Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2008

01-11-2008 | Erratum

Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98

Authors: Dieter Koeberle, Beat Thuerlimann

Published in: Breast Cancer Research and Treatment | Issue 2/2008

Login to get access

Excerpt

Due to an oversight, Financial Disclosure of the Authors in the above referenced supplement was not published as required. All authors have acknowledged and signed a statement of Financial Disclosure/Conflict of Interest and certify that no honoraria for the work therein were received. …
Metadata
Title
Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98
Authors
Dieter Koeberle
Beat Thuerlimann
Publication date
01-11-2008
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9858-3

Other articles of this Issue 2/2008

Breast Cancer Research and Treatment 2/2008 Go to the issue

Erratum

The discovery and mechanism of action of letrozole

Preclinical Study

Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells

Preclinical Study

YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer

Letter to the Editor

The LCT 13910 C/T polymorphism as a risk factor for osteoporosis, has no impact on metastatic bone disease in breast cancer

Preclinical Study

Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers

Preclinical Study

Role of non-receptor and receptor tyrosine kinases (TKs) in the antitumor action of α-difluoromethylornithine (DFMO) in breast cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits